Drug Discovery Today

NOVEMBER 27, 2019

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year. Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction. The collaboration aims to provide a unique solution for future assessment of novel therapeutics.

Development 40

Development Drugs 40

Drug Discovery Today

NOVEMBER 27, 2019

When our skin is damaged, a whole set of biological processes springs into action to heal the wound. Now, researchers from the VIB-UGent Center for Inflammation Research have shown that one of the molecules involved in this, HMGB1, slows down wound healing. It is, however, also essential for tumor formation at sites of previous injury. The researchers found that HMGB1 controls the actions of neutrophils, a specific type of immune cells, in skin wounds and that this is crucial for cancer initiati

Research 40

Research 40